Qianjiang Yong'an Pharmaceutical Co., Ltd.
Special Report on Non-Operating Fund Occupation and Other Related Party Fund Transactions
Report No. Sin-Accountant-Report-Letter [2026] No. ZE10122
To all shareholders of Qianjiang Yong'an Pharmaceutical Co., Ltd.:
We have audited the financial statements of Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as "Yong'an Pharmaceutical") for the year 2025, including the consolidated and parent company balance sheets as of December 31, 2025, the consolidated and parent company income statements, the consolidated and parent company cash flow statements, the consolidated and parent company statements of changes in owners' equity, and the related financial statement notes. We issued an unqualified audit opinion on April 15, 2026, with report number Sin-Accountant-Report-Letter [2026] No. ZE10121.
Yong'an Pharmaceutical's management has prepared the attached summary table of non-operating fund occupation and other related party fund transactions for the year 2025 in accordance with the "Supervisory Requirements for Listed Companies on Fund Transactions and External Guarantees" (CSRC Announcement [2022] No. 26) and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 1 - Business Handling" issued by the China Securities Regulatory Commission.
The preparation of the summary table and ensuring its truthfulness, accuracy, and completeness are the responsibility of Yong'an Pharmaceutical's management. We have cross-checked the information contained in the summary table with the accounting materials audited by us during our audit of Yong'an Pharmaceutical's 2025 financial statements and the disclosures in the audited financial statements. We found no material inconsistencies.